Neogenomics Laboratories

NeoGenomics News


Special Announcement


NeoGenomics to attend 2023 ASCO® Annual Meeting

NeoGenomics is thrilled to exhibit at the 2023 ASCO® Annual Meeting taking place June 2 - 6, 2023 in Chicago, Illinois. Experts will be holding Q&A sessions in the NeoGenomics booth #5135 to discuss key data from the abstracts being presented. Topics will include their experience with the RaDaR® assay, a liquid biopsy test for molecular/minimal residual disease (MRD) as well as MultiOmyx™. MultiOmyx is NeoGenomics’ proprietary, multiplexed immunofluorescence platform that enables single-cell quantification and advanced spatial analysis for up to 60 proteins in a single FFPE tissue section.

To learn more or RSVP for one of the presentations, click here.


Test Updates


Effective Monday, June 5th, the PD-L1 SP263 FDA (TECENTRIQ®) for NSCLC test name will be changed to PD-L1 SP263 FDA for NSCLC.

  • This test is now the companion diagnostic (CDx) for a second drug, LIBTAYO® (cemiplimab-rwlc). The FDA approved the label expansion for the VENTANA PD-L1 (SP263) Assay on March 6, 2023.
  • Test results will now refer to both therapies and their associated cut-offs; ≥ 1% of tumor cells of any intensity for TECENTRIQ® (atezolizumab) and ≥ 50% of tumor cells (TC) of any intensity for LIBTAYO® (cemiplimab-rwlc).


Effective Monday, June 5th, the NeoTYPE® HRD+ Profile test name will be changed to NeoTYPE® HRR Profile.

  • This change will more closely reflect the reporting output of this test which are gene mutations associated with the homologous recombination repair (HRR) pathways, providing information on if cancer has resulted due to the difficulty in repairing this type of DNA damage known as HRD (homologous recombination deficient).
  • Knowing HRR gene mutation status is important for PARP inhibition targeting in a variety of tumor types including breast, ovarian, pancreatic, and prostate.

Test requisitions will reflect both of these test name changes in the next revision update scheduled for the July timeframe.


Test Discontinuations

NeoTYPE® Myeloid Disorders Profile Effective July 1st, this NGS panel will be discontinued from the test menu. As a replacement, please consider the new and enhanced Neo Comprehensive – Myeloid Disorders, a comprehensive NGS genomic profile detecting both DNA and RNA alterations in 164 genes associated with myeloid neoplasms.

  • Orders for the NeoTYPE® Myeloid Disorders Profile will NOT be automatically converted to the new Neo Comprehensive – Myeloid Disorders profile beginning July 1, 2023. To avoid testing delays, please make sure to order the new test using the appropriate requisition form or the online ordering portal.
  • For pricing information and any questions, please contact your local NeoGenomics sales rep or the Client Services team at 1.866.776.5907 option 3.


Molecular Test DiscontinuationsEffective July 1st, the below molecular tests will be discontinued in order to streamline our test menu for operational efficiency. Replacement options have been listed for your reference. Please visit Neo website for complete test directory.


Discontinued Test

Replacement Option

BCL2 Translocation, t(14;18)

IgH/BCL2 t(14;18) by FISH

BCL1 Translocation, t(11;14)

CCND1(BCL1)/IgH t(11;14) by FISH

EGFRvIII Analysis

Neo Comprehensive – Solid Tumor or NeoTYPE DNA & RNA - Brain

We thank you for your continued trust in our service to support your patient care.


Interface Updates

For the list of interface-related test changes that will occur on Monday June 5th, click here for a downloadable document to view the impacted interface test codes.